帕罗西汀联合奥氮平治疗抑郁症的meta分析

doi:10.20047/j.issn1673-7210.2022.26.31

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (2685 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To systematically evaluate the efficacy and safety of Paroxetine combined with Olanzapine in the treatment of depression. Methods The search formula was compiled with the search words “paroxetine”, “olanzapine”, and “depression”, the academic papers in the medical databases such as VIP, the Cochrane Library, CNKI, Web of Sciencecbm core collection database, PubMed, and Wanfang Data were searched and screened. The bias risk assessment and meta analysis of the included literature were carried out through the RevMan 5.3 software, the retrieval period is from the establishment of each database to May 2022. Results A total of 11 randomized controlled trials were included. The results of meta-analysis showed that the Hamilton depression scale of the observation group was lower than that of the control group (MD = -4.27, 95%CI:-5.73 to -2.80, P ＜ 0.000 01), and the total effective number was higher than that of the control group (RR = 1.13, 95%CI:1.03 to 1.24, P = 0.01). There was no significant difference in the total number of adverse reactions between the two groups (RR = 0.77, 95%CI: 0.27 to 2.23, P = 0.63). Conclusion Paroxetine combined with Olanzapine is effective and safe in the treatment of depression, which is worthy of clinical promotion.

Key words： Paroxetine Olanzapine Depression Hamilton depression scale Meta analysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAN Xiyou

Cite this article:

ZHAN Xiyou. Meta analysis of Paroxetine combined with Olanzapine in the treatment of depression[J]. 中国医药导报, 2022, 19(26): 137-141.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2022.26.31 OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I26/137

[1] Bucciarelli V，Caterino AL，Bianco F，et al. Depression and cardiovascular Disease：the deep blue sea of women’s heart [J]. Trends Cardiovasc Med，2020，30（3）：170-176.
[2] Rajan S，McKee M，Rangarajan S，et al. Association of symptoms of depression with cardiovascular disease and mortality in low-，middle-，and high-income countries [J]. JAMA Psychiatry，2020，77（10）：1052-1063.
[3] Graham D，Wu QX，Gilligan I，et al. Improvement of late life depression after therapeutic enoxaparin：two case reports [J]. Australas Psychiatry，2018，26（5）：534-536.
[4] Wysokinski A，Szczepocka E. Red blood cells parameters in patients with acute schizophrenia，unipolar depression and bipolar disorder [J]. Psychiatr Danub，2018，30（3）：323-330.
[5] Huang YQ，Wang Y，Wang H，et al. Prevalence of mental disorders in China：A cross-sectional epidemiological study [J]. Lancet Psychiatry，2019，6（3）： 211-224.
[6] Amato L，Vecchi S，Barbui C，et al. Systematic review to evaluate the efficacy，acceptability and safety of second-generation antipsychotics for the treatment of unipolar and bipolar depression [J]. Recenti Prog Med，2018，109（10）：474-486.
[7] Town JM，Abbass A，Driessen E，et al. Updating the evidence and recommendations for short-term psychodynamic psychotherapy in the treatment of major depressive disorder in adults [J]. Can J Psychiatry，2017，62（1）：73-74.
[8] Liu XJ，Zhang L，Zhang YF，et al. Echogenic alteration in the raphe nuclei measured by transcranial sonography in patients with parkinson disease and depression [J]. Medicine（Baltimore），2018，97（50）：e13524-e13528.
[9] Zayed Y，Barbarawi M，Kheiri B，et al. Haloperidol for the management of delirium in adult intensive care unit patients： a systematic review and meta-analysis of randomized controlled trials [J]. J Crit Care，2019，50（1）：280-286.
[10] Kanova M，Sklienka P，Roman K，et al. Incidence and risk factors for delirium development in ICU patients-prospective observational study [J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub，2017，161（2）：187-196.
[11] 罗捷，冉江峰.国产帕罗西汀联合奥氮平治疗难治性抑郁症的对照研究[J].重庆医学，2009，38（7）：777-778.
[12] 彭成国，王高华，张新风，等.帕罗西汀合并小剂量奥氮平治疗抑郁症伴失眠患者的对照研究[J].海南医学院学报，2014，20（9）：1289-1293.
[13] 王鸿儒.帕罗西汀合并小剂量奥氮平治疗抑郁症伴失眠患者的对照研究[D].济南：山东大学，2012.
[14] 霍健，苏兴利，王爽，等.帕罗西汀联合奥氮平对抑郁症患者的疗效[J].神经损伤与功能重建，2017，12（4）：366-372.
[15] 任宏泉，王维扬，郭操.帕罗西汀联合奥氮平治疗抑郁症60例临床观察[J].山东医药，2008，48（31）：66-67.
[16] 刘虹.帕罗西汀联合奥氮平治疗抑郁症200例[J].中国药业，2012，21（9）：63-64.
[17] 庞春霞.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍100例[J].中国药业，2016，25（9）：92-94.
[18] 陈正平，余关茂，郭剑锋.帕罗西汀联合奥氮平治疗抑郁症并发睡眠障碍临床观察[J].中国药师，2015，18（2）：273-275.
[19] 杨冬林，刘立芬，郝英霞，等.帕罗西汀联合小剂量奥氮平对抑郁症伴失眠患者睡眠进程和睡眠结构的影响[J].中国药房，2016，27（6）：743-745.
[20] 俞锴，郑亚丽.帕罗西汀联合小剂量奥氮平在首发老年抑郁症患者中的应用[J].实用药物与临床，2013，16（11）：1032-1034.
[21] 温天明.帕罗西汀治疗抑郁症早期合用小剂量奥氮平临床观察[J].四川医学，2013，34（1）：69-71.
[22] Wang N，Zheng N，Dong M，et al. Paroxetine combined with olanzapine in the treatment of schizophrenia [J]. Pak J Med Sci，2020，36（3）：516-520.
[23] Muraosa H，Suzuki A，Noto K，et al. Musical Hallucinations Induced by Conventional Doses of Paroxetine [J]. Am J Case Rep，2020，21（1）：e926735-e926736.
[24] Uguz F. A New Safety Scoring System for the Use of Psychotropic Drugs During Lactation [J]. Am J Ther，2021，28（1）：e118-e126.
[25] Cabarcos-Fernández P，Tabernero-Duque MJ，?譧lvarez-Freire I，et al. Determination of Seven Antidepressants in Pericardial Fluid by Means of Dispersive Liquid-Liquid Microextraction（DLLME） and Gas Chromatography-Mass Spectrometry（GC/MS） [J]. J Anal Toxicol，2021，46（2）：146-156.